title: A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias.
abstract: B-lineage acute lymphoblastic leukemia (ALL) arises by transformation of a progenitor (pre-B) cell. Cure rates in adults remain low and treatment is complicated by support provided by the microenvironment to the leukemic cells, indicating an urgent need to better understand the factors that promote their survival. B-cell-activating factor (BAFF) and its receptor BAFF-R are important for survival and growth of mature normal and malignant B cells but are not expressed on pre-B cells. Unexpectedly, all cells in the primary Philadelphia chromosome (Ph)-positive and Ph-negative ALL samples tested were positive for high BAFF-R cell surface expression. BAFF-R was fully competent to bind BAFF, and stimulation of the receptor activated both the classic and the noncanonical NF-kappaB pathways. Recombinant BAFF supported survival of the ALL cells in the absence of stroma, and it significantly attenuated the rate of apoptosis caused by exposure to nilotinib, a drug used therapeutically to treat Ph-positive ALLs. Surprisingly, BAFF mRNA and protein were also expressed in the same cells but BAFF was not shed into the medium. Our report is the first showing universal expression of BAFF-R by pre-B ALL cells and opens the possibility of blocking its function as an adjuvant therapeutic strategy.
authors.affiliation: Section of Molecular Carcinogenesis, Division of Hematology/Oncology, Childrens Hospital Los Angeles, CA 90027, USA.
authors.forename: Reshmi
authors.initials: R
authors.lastname: Parameswaran
authors.forename: Markus
authors.initials: M
authors.lastname: Müschen
authors.forename: Yong-Mi
authors.initials: YM
authors.lastname: Kim
authors.forename: John
authors.initials: J
authors.lastname: Groffen
authors.forename: Nora
authors.initials: N
authors.lastname: Heisterkamp
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D053264:B-Cell Activating Factor / Q000378:metabolism / Q000494:pharmacology; D053265:B-Cell Activation Factor Receptor / Q000096:biosynthesis* / Q000235:genetics; D001854:Bone Marrow Cells / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D019169:Jurkat Cells; D051379:Mice; D016688:Mice, Inbred NOD; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D011994:Recombinant Proteins / Q000494:pharmacology; D015398:Signal Transduction
chemical_list: D053264:B-Cell Activating Factor; D053265:B-Cell Activation Factor Receptor; D012333:RNA, Messenger; D011994:Recombinant Proteins; C435926:TNFRSF13C protein, human
references.citation: Blood. 2007 Dec 1;110(12):3959-67
references.pmid: 17687108
references.citation: Br J Haematol. 1996 Jan;92(1):97-103
references.pmid: 8562418
references.citation: Leukemia. 2000 Mar;14(3):399-402
references.pmid: 10720133
references.citation: Cell Biochem Biophys. 2009;53(1):1-16
references.pmid: 19034695
references.citation: Leuk Lymphoma. 1995 Jun;18(1-2):1-16
references.pmid: 8580810
references.citation: Immunity. 2004 Apr;20(4):441-53
references.pmid: 15084273
references.citation: Klin Padiatr. 1997 Jul-Aug;209(4):178-85
references.pmid: 9293448
references.citation: Ann Rheum Dis. 2007 Jun;66(6):790-7
references.pmid: 17185325
references.citation: J Leukoc Biol. 2009 Aug;86(2):349-59
references.pmid: 19406831
references.citation: Hum Pathol. 2005 Oct;36(10):1113-9
references.pmid: 16226112
references.citation: Blood. 2002 Oct 15;100(8):2973-9
references.pmid: 12351410
references.citation: Eur J Immunol. 1989 Feb;19(2):347-56
references.pmid: 2784769
references.citation: J Exp Med. 1978 Dec 1;148(6):1570-8
references.pmid: 309923
references.citation: Science. 2001 Sep 14;293(5537):2108-11
references.pmid: 11509692
references.citation: Trends Immunol. 2004 Jun;25(6):280-8
references.pmid: 15145317
references.citation: Blood. 1994 Feb 1;83(3):758-66
references.pmid: 7507732
references.citation: J Exp Med. 1999 Jun 7;189(11):1747-56
references.pmid: 10359578
references.citation: Nat Rev Immunol. 2002 Jul;2(7):465-75
references.pmid: 12094221
references.citation: Immunity. 2002 Oct;17(4):515-24
references.pmid: 12387744
references.citation: J Immunol. 2004 Mar 1;172(5):3268-79
references.pmid: 14978135
references.citation: J Exp Med. 1998 Jan 19;187(2):185-96
references.pmid: 9432976
references.citation: Clin Ther. 2008 Nov;30(11):1956-75
references.pmid: 19108785
references.citation: Immunity. 2006 Jun;24(6):729-739
references.pmid: 16782029
references.citation: Blood. 2004 Oct 15;104(8):2247-53
references.pmid: 15251985
references.citation: Blood. 2007 Jan 15;109(2):703-10
references.pmid: 16973958
references.citation: Leukemia. 2007 Jun;21(6):1249-57
references.pmid: 17410186
references.citation: Leukemia. 2000 Sep;14(9):1614-20
references.pmid: 10995008
references.citation: Leukemia. 2006 Jul;20(7):1313-5
references.pmid: 16617317
references.citation: Blood. 1999 Jun 1;93(11):3983-93
references.pmid: 10339508
references.citation: Lancet. 2008 Mar 22;371(9617):1030-43
references.pmid: 18358930
references.citation: Exp Hematol. 1985 Aug;13(7):664-9
references.pmid: 3861327
references.citation: Blood. 2004 Apr 15;103(8):3148-57
references.pmid: 15070697
references.citation: Science. 2001 Sep 14;293(5537):2111-4
references.pmid: 11509691
references.citation: Nat Rev Cancer. 2009 Sep;9(9):665-74
references.pmid: 19693095
references.citation: Immunology. 2006 Jul;118(3):281-92
references.pmid: 16827889
references.citation: Immunity. 2006 Sep;25(3):403-15
references.pmid: 16973390
references.citation: Nat Immunol. 2002 Oct;3(10):958-65
references.pmid: 12352969
references.citation: Blood. 1992 May 1;79(9):2370-7
references.pmid: 1373973
references.citation: Annu Rev Immunol. 2003;21:231-64
references.pmid: 12427767
references.citation: Cancer Res. 2006 May 15;66(10):5387-93
references.pmid: 16707466
references.citation: Cancer Res. 2005 Apr 15;65(8):3290-8
references.pmid: 15833862
references.citation: Br J Haematol. 2007 Aug;138(3):338-48
references.pmid: 17614820
references.citation: J Immunol. 2004 Jul 15;173(2):807-17
references.pmid: 15240667
references.citation: Leuk Lymphoma. 2004 Jun;45(6):1181-4
references.pmid: 15359998
references.citation: J Immunol. 2000 Aug 1;165(3):1322-30
references.pmid: 10903733
references.citation: J Exp Med. 2000 Jul 3;192(1):137-43
references.pmid: 10880535
references.citation: Nat Rev Immunol. 2009 Jul;9(7):491-502
references.pmid: 19521398